|
The
Risk of Detectable HIV-1 RNA Loads or of PI or Lamivudine Resistance
Is Significantly Higher in Nelfinavir-treated Patients Than in Lopinavir/ritonavir-treated
Patients
Relationships between adherence to
protease inhibitor (PI)-based therapy and resistance development
have not been fully characterized.
Abbott scientists conducted a double-blind, randomized, controlled
study of lopinavir/ritonavir
(Kaletra) versus nelfinavir
(Viracept), each administered with stavudine
(Zerit) and lamivudine
(Epivir), in 653 antiretroviral-naive, human immunodeficiency
virus (HIV)-1-infected patients.
Relationships between adherence and probability of resistance
development were evaluated by local linear regression
or logistic regression.
Results
·
A
higher risk of detectable HIV-1 RNA loads after week 24 was associated
with lower adherence and nelfinavir use.
·
Among
all nelfinavir-treated patients, a bell-shaped relationship between
adherence and the risk of nelfinavir resistance was observed, with
a maximum probability of 20% at 85%-90% adherence.
·
No
lopinavir resistance was observed.
·
A
bell-shaped relationship was also observed for the probability of
lamivudine resistance, with a maximum probability of 50% at 75%-80%
adherence to nelfinavir and of 15% at 80%-85% adherence to lopinavir/ritonavir.
Conclusions
The authors conclude, “Bell-shaped relationships between adherence
and resistance were observed.”
“Irrespective of adherence level, the risk of detectable HIV-1
RNA loads or of PI or lamivudine resistance was significantly higher
in nelfinavir-treated patients than in lopinavir/ritonavir-treated
patients.”
Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott
Park, Illinois, USA.
05/20/05
Reference
M
S King, S C Brun and D J Kempf. Relationship between Adherence
and the Development of Resistance in Antiretroviral-Naive, HIV-1-Infected
Patients Receiving Lopinavir/Ritonavir or Nelfinavir. Journal of Infectious Diseases
191(12):2046-52. June 15, 2005.
Link to Index of All HIV and AIDS
Articles by Topic
|